KEAP1 and neoplasm: PCSK9 inhibition disrupted the p62/Keap1/Nrf2 antioxidant axis, effectively disrupting tumor metabolism, inducing metabolic exhaustion, and increasing cancer cell vulnerability to iron‐induced lipid peroxidation, thus suggesting that anti‐PCSK9 therapy is an effective treatment for liver cancer [152].